ArticleACS chemical neuroscience2022
Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis.
Open access · greenAbstract read
In one paragraph
Article in ACS chemical neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Advances in the Rational Design, Mechanisms, and Applications of Lanthanide Nanoparticles for the Regulation of Reactive Oxygen Species.International journal of nanomedicine · 2026Review
- Low-Dimensional Nanomaterials in Alzheimer's Disease: Current Applications.Current Alzheimer research · 2026Review
- Cerium-based nanoparticles for neurodegeneration: emerging redox therapeutics beyond pharmaceuticals.RSC advances · 2025Review
- Europium-doped cerium oxide nanoparticle-impregnated Hyalgan® (CartiOxgel): an intra-articular contrast agent for X-ray CT and optical imaging.RSC advances · 2025Article
- Ultrasonic-assisted europium decorated cuprous oxide nanoparticles: exploring their photothermal capabilities and antioxidant properties for biomedical applications.RSC advances · 2025Article
- Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- MnTheranostics · 2025Article
- Europium oxide nanoparticles (EONP) enhance the cryoprotective effects of chilled rabbit semen preservation via antioxidant and mitochondrial enhancement.Frontiers in veterinary science · 2025Article
- Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Ceria nanoparticles: biomedical applications and toxicity.Journal of Zhejiang University. Science. B · 2024Review
- Influence of EuInternational journal of molecular sciences · 2024Article
- The Impressive Anti-Inflammatory Activity of Cerium Oxide Nanoparticles: More than Redox?Nanomaterials (Basel, Switzerland) · 2023Review
- Nano transdermal system combining mitochondria-targeting cerium oxide nanoparticles with all-trans retinoic acid for psoriasis.Asian journal of pharmaceutical sciences · 2023Article
- The biological functions of europium-containing biomaterials: A systematic review.Materials today. Bio · 2023Review
- Progress in bioactive surface coatings on biodegradable Mg alloys: A critical review towards clinical translation.Bioactive materials · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Jatin MachhiDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Pravin YeapuriDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Milica MarkovicDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Milankumar PatelDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Wenhui YanDepartment of Pharmacology, School of Basic Medical Science, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China.
Yaman LuDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Jacob D CohenDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Mahmudul HasanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Mai Mohamed AbdelmoatyDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
You ZhouCenter for Biotechnology, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, United States.
Huangui XiongDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Xinglong WangDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
R Lee MosleyDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.ORCID 0000-0002-7831-0370
Bhavesh D KevadiyaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.ORCID 0000-0002-9119-7798
University of Nebraska Medical Center · USNebraska Medical Center · USUniversity of Nebraska–Lincoln · USXi'an Jiaotong University · CN
Funding
Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BUCH, SHILPA J., FOX, HOWARD S · 2000 to 2021
$37.7MTargeted mass spectrometry approaches to understand CART processing and recepter interactionsP20GM113126 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI RAZAVI RIZI, MOHAMMAD · 2016 to 2025
$20.8MTargeted Neuro Protection of HIV-1 Associated Neurologic DiseaseP01MH064570 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2001 to 2014
$19.4MPharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8MNeuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3MProteomics CoreP01NS043985 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2003 to 2012
$11.8MRole of EAAT2 and AEG-1 in Astrocyte Dysfunction and NeurodegenerationP01NS031492 · NINDS · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI FISHER, PAUL B · 1993 to 2007
$10.9MNanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7MProdrug Formulations Create Sustained-Release AntiretroviralsR01AI145542 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$5.3MTargeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirsR01MH121402 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$4.9MImmunovascular interactions in postoperative delirium superimposed on dementia (DSD).RF1AG079138 · NIA · DUKE UNIVERSITY · PI GELBARD, HARRIS A, TERRANDO, NICCOLO · 2022 to 2025
$3.6MCombined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5MNIAID NIH HHS R01 AI145542NIAID NIH HHS R01 AI158160NIA NIH HHS R01 AG043540NIA NIH HHS RF1 AG079138NIDA NIH HHS P01 DA028555NIDA NIH HHS R01 DA050540NIGMS NIH HHS P20 GM113126NIMH NIH HHS P01 MH064570NIMH NIH HHS P30 MH062261NIMH NIH HHS R01 MH115860NIMH NIH HHS R01 MH121402NINDS NIH HHS P01 NS031492NINDS NIH HHS P01 NS043985NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder. Pathologically, the disease is characterized by the deposition of amyloid beta (Aβ) plaques and the presence of neurofibrillary tangles. These drive microglia neuroinflammation and consequent neurodegeneration. While the means to affect Aβ plaque accumulation pharmacologically was achieved, how it affects disease outcomes remains uncertain. Cerium oxide (CeO
Indexed as
Alzheimer DiseaseNanoparticlesAmyloid beta-PeptidesAnimalsCeriumEuropiumHomeostasisMiceMice, TransgenicMicrogliaPlaque, AmyloidAmyloid beta-Peptidesceric oxideCeriumEuropiumAlzheimer’s disease (AD)amyloid beta (Aβ)BV2 cells and immune modulationcerium oxideeuropium-doped cerium oxide nanoparticles (EuCeO2NPs)microglia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.